Amundi Asset Management US’s Neurocrine Biosciences NBIX Stock Holding History

Amundi Asset Management US’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2021 Q1	$9.75M	Buy	100,260 +9,151	+10%	+$890K	0.01%	848
2020 Q4	$8.73M	Sell	91,109 -28,379	-24%	-$2.72M	0.01%	848
2020 Q3	$11.5M	Buy	119,488 +6,615	+6%	+$636K	0.01%	697
2020 Q2	$13.8M	Buy	112,873 +3,272	+3%	+$399K	0.02%	609
2020 Q1	$9.49M	Buy	109,601 +14,334	+15%	+$1.24M	0.02%	577
2019 Q4	$10.2M	Buy	95,267 +28,217	+42%	+$3.03M	0.01%	741
2019 Q3	$6.04M	Sell	67,050 -33,866	-34%	-$3.05M	0.01%	807
2019 Q2	$8.52M	Buy	+100,916	New	+$8.52M	0.01%	815
2018 Q4	–	Sell	-67,900	Closed	-$8.35M	–	1624
2018 Q3	$8.35M	Sell	67,900 -1,400	-2%	-$172K	0.01%	784
2018 Q2	$6.81M	Buy	69,300 +10,700	+18%	+$1.05M	0.01%	834
2018 Q1	$4.86M	Buy	+58,600	New	+$4.86M	0.01%	868
2017 Q4	–	Sell	-23,783	Closed	-$1.46M	–	1558
2017 Q3	$1.46M	Buy	+23,783	New	+$1.46M	﹤0.01%	469
2017 Q1	–	Sell	-153,347	Closed	-$5.94M	–	551
2016 Q4	$5.94M	Sell	153,347 -3,818	-2%	-$148K	0.02%	378
2016 Q3	$7.96M	Sell	157,165 -836	-0.5%	-$42.3K	0.03%	349
2016 Q2	$7.18M	Sell	158,001 -35,025	-18%	-$1.59M	0.03%	352
2016 Q1	$7.63M	Buy	193,026 +3,553	+2%	+$141K	0.03%	336
2015 Q4	$10.7M	Buy	189,473 +72,801	+62%	+$4.12M	0.04%	302
2015 Q3	$4.64M	Sell	116,672 -27,643	-19%	-$1.1M	0.02%	434
2015 Q2	$6.89M	Sell	144,315 -49,556	-26%	-$2.37M	0.03%	405
2015 Q1	$7.7M	Sell	193,871 -44,750	-19%	-$1.78M	0.03%	384
2014 Q4	$5.33M	Sell	238,621 -265,317	-53%	-$5.93M	0.02%	443
2014 Q3	$7.9M	Sell	503,938 -7,679	-2%	-$120K	0.03%	373
2014 Q2	$7.59M	Buy	511,617 +77,103	+18%	+$1.14M	0.03%	395
2014 Q1	$7M	Sell	434,514 -90,009	-17%	-$1.45M	0.03%	400
2013 Q4	$4.9M	Buy	524,523 +50,037	+11%	+$467K	0.02%	455
2013 Q3	$5.37M	Buy	474,486 +226,486	+91%	+$2.56M	0.02%	445
2013 Q2	$3.32M	Buy	+248,000	New	+$3.32M	0.01%	497